In Feb. 2021, Dr. Ren became Chief Scientific Officer and Head of Research and Development at Insilico and has since grown a team of 70 scientists in Shanghai across a range of specialties, including biology, bioinformatics, medicinal chemistry, computer aided design and drafting, preclinical, and clinical expertise. This team discovers novel targets using PandaOmics and designs novel molecules for those targets utilizing Insilico's Chemistry42 platform. The most promising molecules — based on successful scores across a series of measures — are then selected for synthesis and test through cells, tissues, and animals towards Investigational New Drug (IND) applications and then human studies. At the far end of Insilico's pipeline is InClinico — its AI platform for predicting the outcome of clinical trials.